Atovaquone and Proguanil Hydrochloride: A Review of Nonclinical Studies

被引:0
作者
Pudney, Mary [1 ]
Gutteridge, Win [2 ,3 ]
Zeman, Anton [4 ]
Dickins, Maurice [5 ]
Woolley, Joseph L. [6 ]
机构
[1] Glaxo Wellcome Res & Dev, Med Res Ctr, Syst Biol Unit, Stevenage, England
[2] UNDP Special Programme Res & Training Trop Dis TDR, Geneva, Switzerland
[3] Wellcome Res Labs, Res Div, Beckenham, England
[4] Glaxo Wellcome Inc, Div Med Safety Evaluat, Res Triangle Pk, NC USA
[5] Glaxo Wellcome Res & Dev, Int Dev Bioanal & Drug Metab, Ware, England
[6] Glaxo Wellcome Inc, Div Bioanal & Drug Metab, Res Triangle Pk, NC USA
关键词
D O I
10.1093/jtm/6.suppl.S8
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: Safe and effective antimalarial drugs are needed for treatment and prophylaxis of malaria. The combination of atovaquone and proguanil hydrochloride is a new antimalarial drug combination that has recently become available in many countries. Methods: Data were reviewed from nonclinical studies evaluating the microbiology, secondary pharmacology, pharmacokinetics, and toxicology of atovaquone and proguanil hydrochloride. Results: Atovaquone is highly active against asexual erythrocytic stages of Plasmodium falciparum in vitro (IC60 0.7-6 nM) and in animal models. Proguanil per se has only weak antimalarial activity in vitro (IC50 2.4-19 p.M), and its effectiveness depends on the active metabolite cycloguanil (IC60 0.5-2.5 nM). The combination of atovaquone and proguanil is synergistic in vitro. Both drugs also have activity against gametocytes and pre-erythrocytic (hepatic) stages of malaria parasites. Atovaquone is a ubiquinone antagonist that inhibits mitochondrial electron transport and collapses mitochondrial membrane potential. The proguanil metabolite cycloguanil is a dihydrofolate reductase inhibitor, but the mode of action of proguanil is unknown. In screening evaluations of secondary pharmacology, neither atovaquone nor proguanil had activity that adversely affected gastrointestinal, cardiovascular, or central or autonomic nervous system functions at clinically relevant concentrations. After oral administration, atovaquone exposure is extensive in rats but limited in dogs, while proguanil and cycloguanil exposure is extensive in dogs but limited in rats. In both species, toxicity was related to proguanil exposure, the principal manifestations being salivation, emesis, and loss of body weight. Neither atovaquone nor proguanil was teratogenic or mutagenic. An increased incidence of hepatic adenomas and adenocarcinomas was seen in mice, but not rats, after lifetime exposure to atovaquone, and appears to be related to species-specific differences in hepatic enzymatic activity. No additional toxicity was evident in animals treated with the combination of atovaquone and proguanil hydrochloride compared to those treated with either drug alone. Conclusion: Nonclinical studies of atovaquone and proguanil hydrochloride supported the clinical development of this combination for treatment and prophylaxis of malaria.
引用
收藏
页码:S8 / S12
页数:5
相关论文
共 50 条
[21]   Atovaquone/proguanil: The need for family protection [J].
Kain, KC .
JOURNAL OF TRAVEL MEDICINE, 2003, 10 :S8-S12
[22]   Atovaquone/proguanil for Plasmodium falciparum malaria [J].
Sehdev, PS .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2002, 21 (08) :787-789
[23]   Atovaquone and proguanil for Plasmodium falciparum malaria [J].
Radloff, PD ;
Philipps, J ;
Nkeyi, M ;
Hutchinson, D ;
Kremsner, PG .
LANCET, 1996, 347 (9014) :1511-1514
[24]   Atovaquone/proguanil for the treatment and prevention of malaria [J].
Richard D. Pearson .
Current Infectious Disease Reports, 2001, 3 (1) :47-49
[25]   Quinine-resistant severe falciparum malaria effectively treated with atovaquone and proguanil hydrochloride combination therapy [J].
Uchiyama, H ;
Okamoto, A ;
Sato, K ;
Yamada, T ;
Murakami, S ;
Yoneda, S ;
Karta, Y ;
Tegoshi, T ;
Arizono, N .
INTERNAL MEDICINE, 2004, 43 (07) :624-627
[26]   Combination atovaquone and proguanil hydrochloride vs. halofantrine for treatment of acute Plasmodium falciparum malaria in children [J].
Anabwani, G ;
Canfield, CJ ;
Hutchinson, DBA .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1999, 18 (05) :456-461
[27]   The safety of atovaquone-proguanil for the prevention and treatment of malaria in pregnancy: A systematic review [J].
Andrejko, Kristin L. ;
Mayer, Romana C. ;
Kovacs, Stephanie ;
Slutsker, Emma ;
Bartlett, Emily ;
Tan, Kathrine R. ;
Gutman, Julie R. .
TRAVEL MEDICINE AND INFECTIOUS DISEASE, 2019, 27 :20-26
[28]   Lack of a pharmacokinetic interaction between atovaquone and proguanil [J].
Gillotin, C ;
Mamet, JP ;
Veronese, L .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 55 (04) :311-315
[29]   Atovaquone-proguanil for treating uncomplicated malaria [J].
Osei-Akoto, A. ;
Orton, L. ;
Owusu-Ofori, S. P. O. .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2005, (04)
[30]   Proguanil polymorphism does not affect the antimalarial activity of proguanil combined with atovaquone in vitro [J].
Edstein, MD ;
Yeo, AET ;
Kyle, DE ;
Looareesuwan, S ;
Wilairatana, P ;
Rieckmann, KH .
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 1996, 90 (04) :418-421